Compliance Rate
Compliance Rate
0.0%
Compliant submissions
0
Incompliant submissions
1
Total trials
1
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: -
End: -
Due: -
Phase: N/A
Priority: Normal
Start: -
End: -
Due: -
Phase: N/A
Priority: Normal
Start: -
End: -
Due: -
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible) | NCT00002079 | G D Searle | user2@example.com | None | - | - | - | - | - | 2025-07-14 |
| Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex | NCT00000692 | G D Searle | user3@example.com | Incompliant | - | - | - | 2025-07-01 | - | 2025-07-14 |
| Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3 | NCT00001993 | G D Searle | user2@example.com | None | - | - | - | - | - | 2025-07-14 |